Robin Brown, NP
Adult Health · Havre de Grace, MDNPI 1134773922
Payments from drug & device makers
Across 115 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$585
- Lilly USA, LLC$259
- Novo Nordisk$162
- Astellas Pharma US Inc$145
- Pfizer$133
- Sumitomo Pharma America, Inc.$126
- plus $960 from 17 others
What the payments were for
- Food & beverage$2,30197%
- Education$693%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 43 | $585 |
| Lilly USA, LLC | 13 | $259 |
| Novo Nordisk | 8 | $162 |
| Astellas Pharma US Inc | 4 | $145 |
| Pfizer | 7 | $133 |
| Sumitomo Pharma America, Inc. | 1 | $126 |
| GSK | 6 | $122 |
| Amgen | 5 | $97 |
| Hologic Sales And Service, LLC | 1 | $95 |
| Exact Sciences | 3 | $74 |
| Johnson & Johnson | 1 | $71 |
| Phathom Pharmaceuticals, Inc. | 3 | $71 |
| Sanofi Pasteur Inc. | 1 | $70 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $67 |
| Optinose US, Inc. | 3 | $59 |
| AstraZeneca | 3 | $57 |
| Esperion Therapeutics, Inc. | 3 | $53 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Verona Pharma, Inc. | 1 | $18 |
| Bayer | 1 | $16 |
| Mylan Specialty L.p. | 1 | $16 |
| Merck | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GEMTESA$126
How this compares
$2,370 in reported general payments places this provider in the 80th percentile of 542 adult health providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 28 | $57,196 |
| EliquisApixaban | 13 | $20,815 |
| Alosetron Hcl | 12 | $18,751 |
| FarxigaDapagliflozin Propanediol | 11 | $18,232 |
| JanuviaSitagliptin Phosphate | 14 | $17,037 |
| WegovySemaglutide | 12 | $15,553 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $14,364 |
| Atorvastatin Calcium | 212 | $2,876 |
| SynthroidLevothyroxine Sodium | 37 | $2,423 |
| Rosuvastatin Calcium | 105 | $2,254 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 71 | $1,764 |
| Levothyroxine Sodium | 121 | $1,530 |
| Losartan Potassium | 145 | $1,511 |
| Gabapentin | 64 | $1,478 |
| Omeprazole | 81 | $1,360 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $162 | $72,74840 claims |
| PfizerEliquis | $133 | $20,81513 claims |
| AstraZenecaFarxiga | $57 | $18,23211 claims |
| MerckJanuvia | $16 | $17,03714 claims |
| AbbVieSynthroid | $585 | $2,42337 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 542 adult health providers in Maryland.
Other adult health in Havre de Grace
- Lucia NovakCamp Springs$473K
- Caroline RuhlAnnapolis$315K
- Joyce MiskovicHighland$264K
- Christopher RobersonBaltimore$180K
- Amit DhirBaltimore$97K
- Angie PriceBaltimore$96K
- Morgan JoliatSykesville$92K
- Brendon BowerBaltimore$64K
- Caitlin NassBaltimore$46K
- Jane KapustinClarksville$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.